The experiment is divided into two parts: Part 1 and Part 2.Part 1 was the initial treatment patient and Part 2 was the treated patient.

About 125 subjects were planned to be included and assigned to the experimental group and the control group according to 4:1.At the same time, a liver biopsy group was set up in each part of the population to receive liver biopsy during the screening period and 48 weeks after completion of drug administration, which was used to detect HBV DNA, cccDNA, HBsAg, and evaluate the degree of liver inflammation and fibrosis.

Inclusion Criteria:

• Chronic HBV infection population
• HBeAg positive
• HBsAg≥250 IU/mL
• No cirrhosis

Exclusion Criteria:

• AST>5×ULN
• Platelet count less than 90E+09/L
• TBil>1.5×ULN
• albumin<35 g/L
• INR>1.5
• AFP>50 ng/mL